PBH Prestige Consumer Healthcare Inc

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredient in any Ting® Antifungal Spray products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid (either before or after these batch codes) and no other Ting® Antifungal Spray Liquid products are in the scope of this recall and may continue to be used by consumers safely and as intended.

Risk Statement: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin and it potentially can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life threatening. Insight is recalling these products out of an abundance of caution. To date, the Company has not received any serious adverse events related to this recall. Benzene is ubiquitous in the environment. Humans around the world have daily exposures to it indoors and outdoors from multiple sources.

TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid is packaged in blue and white aerosol cans with Lot codes located on the bottom of the can.



Samples of the recalled lots below have been found to contain elevated levels of Benzene related to the propellant that sprays the product out of the can. Benzene is not an ingredient in any Ting products.

ProductNDCLot CodeExpirationPackage Size
TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid63736-819-050H5054507/244.5 oz/128 g
TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid63736-819-051G5064506/254.5 oz/128 g

The affected TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid lots were distributed nationwide in the United States through a limited number of retailers and online.

Insight has notified retailers via overnight mail to remove any remaining recalled product from shelves and follow the instructions provided in the Drug Recall Notification. The company will also offer reimbursement for consumers who have purchased TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid marked with one of the lot codes in the table above. Consumers can contact Insight Pharmaceuticals via e-mail at , through its website at , or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time to receive a full refund by providing a picture of the bottom of the can of the TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid with the affected lot number. Consumers that have product which is being recalled should stop using the product immediately and appropriately discard after taking the picture.

No serious adverse events have been reported to date.

Consumers with questions regarding this recall can contact Insight Pharmaceuticals via e-mail at , through its website at , or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this antifungal product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online:
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

A photo accompanying this announcement is available at



Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
 
EN
02/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prestige Consumer Healthcare Inc

 PRESS RELEASE

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarte...

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of...

 PRESS RELEASE

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected P...

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and . Seventy-five years later, Dramamine, a Prestige Consumer Healthcare brand, thrives as the number one brand for motion sickness relief, but as Dr...

Prestige Consumer Healthcare Inc: 2 directors

Two Directors at Prestige Consumer Healthcare Inc sold after exercising options/sold 56,038 shares at between 67.899USD and 68.353USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Re...

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings Outlook to Approximately $4.33 TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023. “We are pleased with our continued strong results that exceeded our revenue and earnings expe...

 PRESS RELEASE

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1%...

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch